![]() |
|
|
Molecular Pharmacology, Vol 12, 879-886, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics
1 Department of Pharmacology, Northwestern University Medical School, Chicago, Illinois 60611
2 Department of Pharmacology and Toxicology, School of Medicine and Dentistry, University of Rochester,
Rochester, New York 14620
3 Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison,
Madison, Wisconsin 53706
Organ cultures of fetal rat bone were used to test the effects of molecular modification on
the bone-resorbing activity of the vitamin D3 metabolites 25-OH-D3 and 1,25-(OH)2D3.
Addition of 26-hydroxyl group to the 25-OH-D3 side chain reduced the activity more than
10-fold. Shortening the 25-OH-D3 side chain by 1 carbon atom reduced the activity by at
least two orders of magnitude. Removal of the 26- and 27-methyl groups diminished the
bone-resorbing activity still further. 1,25-(OH)2D3 was likewise more active than the
vitamin D3 derivatives with which it was compared. The 3
-hydroxy epimer of 1,25-(OH)2D3 [1,25-(OH)2D3 (3
)] was more than three orders of magnitude less active than
1,25-(OH)2D3. 1,24(R),25-(OH)3D3 was approximately 1/10 as active as 1,25-(OH)2D3.
When the 24-hydroxyl was in the S configuration, the trihydroxy derivative was even
less effective. 1,25-(OH)2D3 was approximately equiactive with 1,25-(OH)2D2. The results illustrate the importance of precise structural characteristics at a number of sites
on the molecule for optimal bone-resorbing activity. The data also show that in terms of
direct effects on bone, no known naturally occurring vitamin D3 metabolite or synthetic
congener surpasses 1,25-(OH)2D3 in activity. A striking correlation exists between the
structure-activity relationships shown here and published studies on the binding of
vitamin D analogues to subcellular "receptors." Good correlations also can be demonstrated between effects of the 1-hydroxylated derivatives on bone resorption in vivo and
in vitro. Greater inconsistencies between results in vitro and in vivo are found with
compounds lacking a 1-hydroxyl group.
This article has been cited by other articles:
![]() |
H. Gelbard, P. Stern, and D. U'Prichard 1 alpha, 25-Dihydroxyvitamin D3 nuclear receptors in pituitary Science, September 12, 1980; 209(4462): 1247 - 1249. [Abstract] [PDF] |
||||